Literature DB >> 21713780

Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity.

Richdeep S Gill1, David P Al-Adra, Jeevan Nagendran, Sandy Campbell, Xinzhe Shi, Erika Haase, Daniel Schiller.   

Abstract

Gastric cancer with peritoneal carcinomatosis has an extremely poor prognosis, which may be improved with cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). We systematically reviewed the literature regarding the efficacy of CRS + HIPEC in these patients. Electronic databases were searched from 2000 to 2010. Following CRS + HIPEC, overall median survival was 7.9 months and improved to 15 months for patients with completeness of cytoreduction scores of 0/1, however with a 30-day mortality rate of 4.8%.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21713780     DOI： 10.1002/jso.22017

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  73 in total

Review 1.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.

Authors:  Ramakrishnan Ayloor Seshadri; Olivier Glehen
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 2.  Updates on Management of Gastric Cancer.

Authors:  Fabian M Johnston; Michael Beckman
Journal:  Curr Oncol Rep       Date:  2019-06-24       Impact factor: 5.075

3.  Peritoneal metastasis in gastric cancer: results from the German database.

Authors:  Beate Rau; Andreas Brandl; Pompiliu Piso; Jörg Pelz; Peter Busch; Cedric Demtröder; Silke Schüle; Hans-Jürgen Schlitt; Marc Roitman; Jürgen Tepel; Udo Sulkowski; Faik Uzunoglu; Michael Hünerbein; Rüdiger Hörbelt; Michael Ströhlein; Stefan Beckert; Ingmar Königsrainer; Alfred Königsrainer
Journal:  Gastric Cancer       Date:  2019-06-21       Impact factor: 7.370

Review 4.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

5.  Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center.

Authors:  Sook Hee Hong; Yu Ri Shin; Sang Young Roh; Eun Kyoung Jeon; Kyo Yung Song; Cho Hyun Park; Hae Myung Jeon; Young Seon Hong
Journal:  Gastric Cancer       Date:  2012-08-17       Impact factor: 7.370

6.  Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis.

Authors:  Paola Fugazzola; Federico Coccolini; Giulia Montori; Marco Ceresoli; Paolo Baggi; Antonio Costanzo; Matteo Tomasoni; Francesco Gregis; Silvia Nozza; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 7.  Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan.

Authors:  Koji Kono; Wei-Peng Yong; Hirokazu Okayama; Asim Shabbir; Tomoyuki Momma; Shinji Ohki; Seiichi Takenoshita; Jimmy So
Journal:  Gastric Cancer       Date:  2016-10-20       Impact factor: 7.370

Review 8.  Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.

Authors:  Daisuke Kobayashi; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2016-11-01       Impact factor: 7.370

9.  Comparison of the outcomes of cytoreductive surgery versus surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: a propensity score matching analysis.

Authors:  Zhou Li; Juan de Dios Redondo Ntutumu; Shengyi Huang; Zhai Cai; Shuai Han; A I Balde; Zeyu Luo; Suzhen Fang
Journal:  Surg Endosc       Date:  2020-07-06       Impact factor: 4.584

Review 10.  Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy.

Authors:  Simon Binder; Andrew L Lewis; J-Matthias Löhr; Michael Keese
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.